Andrew Combs - Mar 1, 2024 Form 4 Insider Report for Prelude Therapeutics Inc (PRLD)

Role
Chief Chemistry Officer
Signature
/s/ Laurent Chardonnet, Attorney-in-Fact
Stock symbol
PRLD
Transactions as of
Mar 1, 2024
Transactions value $
$0
Form type
4
Date filed
3/4/2024, 06:05 PM
Previous filing
Feb 9, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PRLD Employee Stock Option (right to buy) Award $0 +150K $0.00 150K Mar 1, 2024 Common Stock 150K $4.59 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests as to 25% of the total shares on March 1, 2025, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.